To this effect, we observed a significant decrease in the accumulation of both myeloid cells and T cells in the mice liver after treatment with RUNX1 siRNA-immunonano-lipocarriers, which is suggestive of the key contribution of LSEC specific RUNX1 toward increased hepatic inflammation in NASH through an upregulation of adhesion molecules in NASH. The gene discussed is RUNX1; the disease is metabolic dysfunction-associated steatohepatitis.